NA
AMPH icon

NewEdge Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

NewEdge Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,895
Closed -$626K – 3465
2023
Q2 		$626K Sell
10,895
-5,891
-35% -$261K 0.01% 1073
2023
Q1 		$629K Buy
16,786
+16,775
+152,500% +$550K 0.01% 1009
2022
Q4 		$0 Buy
+11
New +$319 ﹤0.01% 4079

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

NewEdge Advisors's AMPH Position: Q3 2023 in Review

NewEdge Advisors sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2023, closing a stake of 10,895 shares — an estimated $626K sold.

NewEdge Advisors first reported a position in AMPH in Q4 2022 and held it in 3 quarters. The position peaked at $629K in Q1 2023. 255 funds tracked by Wall St. Rank hold AMPH as of Q3 2023.

  • NewEdge Advisors reported no remaining Amphastar Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • NewEdge Advisors sold 10,895 Amphastar Pharmaceuticals shares in Q3 2023, an estimated $626K.
  • NewEdge Advisors first reported a position in Amphastar Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • NewEdge Advisors's Amphastar Pharmaceuticals position peaked at $629K in Q1 2023.
  • 255 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2023.

Based on NewEdge Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.